149 related articles for article (PubMed ID: 29676875)
1. [Faster aspart insulin (FIASP®)].
Paquot N; Scheen AJ
Rev Med Liege; 2018 Apr; 73(4):211-215. PubMed ID: 29676875
[TBL] [Abstract][Full Text] [Related]
2. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.
Heise T; Pieber TR; Danne T; Erichsen L; Haahr H
Clin Pharmacokinet; 2017 May; 56(5):551-559. PubMed ID: 28205039
[TBL] [Abstract][Full Text] [Related]
3. Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences.
Haahr H; Heise T
Clin Pharmacokinet; 2020 Feb; 59(2):155-172. PubMed ID: 31667789
[TBL] [Abstract][Full Text] [Related]
4. [Faster Insulin Aspart - a new prandial insulin analogue].
Flekač M
Vnitr Lek; 2017; 63(10):697-702. PubMed ID: 29127752
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.
Heise T; Stender-Petersen K; Hövelmann U; Jacobsen JB; Nosek L; Zijlstra E; Haahr H
Clin Pharmacokinet; 2017 Jun; 56(6):649-660. PubMed ID: 27878566
[TBL] [Abstract][Full Text] [Related]
6. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
Heise T; Hövelmann U; Brøndsted L; Adrian CL; Nosek L; Haahr H
Diabetes Obes Metab; 2015 Jul; 17(7):682-8. PubMed ID: 25846340
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.
Heise T; Zijlstra E; Nosek L; Rikte T; Haahr H
Diabetes Obes Metab; 2017 Feb; 19(2):208-215. PubMed ID: 27709762
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Properties of Faster-Acting Insulin Aspart.
Biester T; Kordonouri O; Danne T
Curr Diab Rep; 2017 Sep; 17(11):101. PubMed ID: 28940145
[TBL] [Abstract][Full Text] [Related]
9. Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart.
Pieber TR; Svehlikova E; Brunner M; Halberg IB; Due Thomsen KM; Haahr H
Diabetes Obes Metab; 2019 Sep; 21(9):2068-2075. PubMed ID: 31069935
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacological and clinical characteristics of Insulin Faster Aspart (Fiasp®)].
Faingold MC; Luquez C; Oviedo A; Puchulu F; Re M
Medicina (B Aires); 2022; 82(5):752-759. PubMed ID: 36220033
[TBL] [Abstract][Full Text] [Related]
11. Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective.
Senior P; Hramiak I
Can J Diabetes; 2019 Oct; 43(7):515-523. PubMed ID: 30872107
[TBL] [Abstract][Full Text] [Related]
12. Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them?
Muchmore DB
J Diabetes Sci Technol; 2018 Jan; 12(1):152-154. PubMed ID: 29291651
[TBL] [Abstract][Full Text] [Related]
13. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice.
Evans M; Ceriello A; Danne T; De Block C; DeVries JH; Lind M; Mathieu C; Nørgaard K; Renard E; Wilmot EG
Diabetes Obes Metab; 2019 Sep; 21(9):2039-2047. PubMed ID: 31144428
[TBL] [Abstract][Full Text] [Related]
14. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
Fath M; Danne T; Biester T; Erichsen L; Kordonouri O; Haahr H
Pediatr Diabetes; 2017 Dec; 18(8):903-910. PubMed ID: 28165180
[TBL] [Abstract][Full Text] [Related]
15. Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus.
Davis A; Kuriakose J; Clements JN
Clin Pharmacokinet; 2019 Apr; 58(4):421-430. PubMed ID: 29978361
[TBL] [Abstract][Full Text] [Related]
16. Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart.
Shiramoto M; Nishida T; Hansen AK; Haahr H
J Diabetes Investig; 2018 Mar; 9(2):303-310. PubMed ID: 28556616
[TBL] [Abstract][Full Text] [Related]
17. The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications.
Owens DR; Bolli GB
Diabetes Obes Metab; 2020 May; 22(5):743-754. PubMed ID: 31930670
[TBL] [Abstract][Full Text] [Related]
18. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes.
Svehlikova E; Mursic I; Augustin T; Magnes C; Gerring D; Jezek J; Schwarzenbacher D; Ratzer M; Wolf M; Howell S; Zakrzewski L; Urschitz M; Tschapeller B; Gatschelhofer C; Feichtner F; Lawrence F; Pieber TR
Diabetes Care; 2021 Feb; 44(2):448-455. PubMed ID: 33328285
[TBL] [Abstract][Full Text] [Related]
20. Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin.
Evans M; Wilkinson M; Giannpolou A
Diabetes Ther; 2019 Oct; 10(5):1793-1800. PubMed ID: 31485918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]